Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome

Journal of Neuroinflammation

Theoharis C Theoharides²  Jennifer Newman¹  Magdalini Vasiadi³ 

[1] Department of Neuroscience, Tufts University, School of Medicine, Boston, MA, USA;Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA;Graduate Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA

关键词: Swim;    Stress;    Skin;    Polyinosinic:polycytidylic acid;    Mast cells;    Isoflavones;    Inflammation;    Fatigue;    Brain;   

Others  :  1150293
DOI  :  10.1186/s12974-014-0168-5

 received in 2014-04-07, accepted in 2014-09-17,  发布年份 2014

【 摘 要 】

Background

Chronic Fatigue Syndrome (CFS) is a neuroimmunoendocrine disease affecting about 1% of the US population, mostly women. It is characterized by debilitating fatigue for six or more months in the absence of cancer or other systemic diseases. Many CFS patients also have fibromyalgia and skin hypersensitivity that worsen with stress. Corticotropin-releasing hormone (CRH) and neurotensin (NT), secreted under stress, activate mast cells (MC) necessary for allergic reactions to release inflammatory mediators that could contribute to CFS symptoms.

Objective

To investigate the effect of isoflavones on the action of polyinosinic:polycytidylic acid (poly(I:C)), with or without swim stress, on mouse locomotor activity and inflammatory mediator expression, as well as on human MC activation.

Methods

Female C57BL/6 mice were randomly divided into four groups: (a) control/no-swim, (b) control/swim, (c) polyinosinic:polycytidylic acid (poly(I:C))/no swim, and (d) polyinosinic:polycytidylic acid (poly(I:C))/swim. Mice were provided with chow low or high in isoflavones for 2 weeks prior to ip injection with 20 mg/kg poly(I:C) followed or not by swim stress for 15 minutes. Locomotor activity was monitored overnight and animals were sacrificed the following day. Brain and skin gene expression, as well as serum levels, of inflammatory mediators were measured. Data were analyzed using the non-parametric Mann-Whitney U-test.

Results

Poly(I:C)-treated mice had decreased locomotor activity over 24 hours, and increased serum levels of TNF-?, IL-6, KC (IL-8/CXCL8 murine homolog), CCL2,3,4,5, CXCL10, as well as brain and skin gene expression of TNF, IL-6, KC (Cxcl1, IL8 murine homolog), CCL2, CCL4, CCL5 and CXCL10. Histidine decarboxylase (HDC) and NT expression were also increased, but only in the skin, over the same period. High isoflavone diet reversed these effects.

Conclusion

Poly(I:C) treatment decreased mouse locomotor activity and increased serum levels and brain and skin gene expression of inflammatory mediators. These effects were inhibited by isoflavones that may prove useful in CFS.

【 授权许可】

   
2014 Vasiadi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C: Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev 2005, 15:29-58.
• [2]Jahan F, Nanji K, Qidwai W, Qasim R: Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. Oman Med J 2012, 27:192-195.
• [3]Anderson VR, Jason LA, Hlavaty LE, Porter N, Cudia J: A review and meta-synthesis of qualitative studies on myalgic encephalomyelitis/chronic fatigue syndrome. Patient Educ Couns 2012, 86:147-155.
• [4]Van't LM, Zielhuis GA, van der Meer JW, Verbeek AL, Bleijenberg G: Fatigue and chronic fatigue syndrome-like complaints in the general population. Eur J Public Health 2010, 20:251-257.
• [5]Griffith JP, Zarrouf FA: A systematic review of chronic fatigue syndrome: don't assume it's depression. Prim Care Companion J Clin Psychiatry 2008, 10:120-128.
• [6]Holgate ST, Komaroff AL, Mangan D, Wessely S: Chronic fatigue syndrome: understanding a complex illness. Nat Rev Neurosci 2011, 12:539-544.
• [7]Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R: Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 2009, 124:189-193.
• [8]Fremont M, Metzger K, Rady H, Hulstaert J, De MK: Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients. In Vivo 2009, 23:209-213.
• [9]Theoharides TC: Atopic conditions in search of pathogenesis and therapy. Clin Ther 2013, 35:544-547.
• [10]Martinez-Martinez LA, Mora T, Vargas A, Fuentes-Iniestra M, Martinez-Lavin M: Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control studies. J Clin Rheumatol 2014, 20:146-150.
• [11]Aaron LA, Buchwald D: Fibromyalgia and other unexplained clinical conditions. Curr Rheumatol 2001, 3:116-122.
• [12]Abbi B, Natelson BH: Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. QJM 2013, 106:3-9.
• [13]Aaron LA, Buchwald D: Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Prac Res Clin Rheumatol 2003, 17:563-574.
• [14]Smith MS, Martin-Herz SP, Womack WM, Marsigan JL: Comparative study of anxiety, depression, somatization, functional disability, and illness attribution in adolescents with chronic fatigue or migraine. Pediatrics 2003, 111:e376-e381.
• [15]Theoharides TC, Cochrane DE: Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004, 146:1-12.
• [16]Gur A, Oktayoglu P: Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: new concepts in treatment. Curr Pharm Des 2008, 14:1274-1294.
• [17]Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V: Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001, 86:3545-3554.
• [18]Crawley E, Hunt L, Stallard P: Anxiety in children with CFS/ME. Eur Child Adolesc Psychiatry 2009, 18:683-689.
• [19]Theoharides TC, Weinkauf C, Conti P: Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol 2004, 24:577-581.
• [20]Maes M, Twisk FN, Ringel K: Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom 2012, 81:286-295.
• [21]Pae CU, Marks DM, Patkar AA, Masand PS, Luyten P, Serretti A: Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother 2009, 10:1561-1570.
• [22]Huang L, Frampton G, Rao A, Zhang KS, Chen W, Lai JM, Yin XY, Walker K, Culbreath B, Leyva-Illades D, Quinn M, McMillin M, Bradley M, Liang LJ, DeMorrow S: Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest 2012, 92:1451-1460.
• [23]Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B: Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012, 26:24-31.
• [24]Dietert RR, Dietert JM: Possible role for early-life immune insult including developmental immunotoxicity in chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME). Toxicology 2008, 247:61-72.
• [25]Bower JE: Fatigue, brain, behavior, and immunity: summary of the 2012 Named Series on fatigue. Brain Behav Immun 2012, 26:1220-1223.
• [26]Klimas NG, Broderick G, Fletcher MA: Biomarkers for chronic fatigue. Brain Behav Immun 2012, 26:1202-1210.
• [27]Blanco I, Beritze N, Arguelles M, Carcaba V, Fernandez F, Janciauskiene S, Oikonomopoulou K, De Serres FJ, Fernandez-Bustillo E, Hollenberg MD: Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010, 29:1403-1412.
• [28]Enestrom S, Bengtsson A, Frodin T: Dermal IgG deposits and increase of mast cells in patients with fibromyalgia-relevant findings or epiphenomena? Scand J Rheumatol 1997, 26:308-313.
• [29]Steinberg P, Pheley A, Peterson PK: Influence of immediate hypersensitivity skin reactions on delayed reactions in patients with chronic fatigue syndrome. J Allergy Clin Immunol 1996, 98:1126-1128.
• [30]Yener M, Erturan I, Ceyhan AM, Inal EE, Kozanoglu OO: The evaluation of prevalence of fibromyalgia in patients with chronic urticaria. Med Sci Monit 2013, 19:757-761.
• [31]Nijs J, De BP, De MK, Demanet C, Vincken W, Schuermans D, McGregor N: Associations between bronchial hyperresponsiveness and immune cell parameters in patients with chronic fatigue syndrome. Chest 2003, 123:998-1007.
• [32]Theoharides TC, Papaliodis D, Tagen M, Konstantinidou A, Kempuraj D, Clemons A: Chronic fatigue syndrome, mast cells, and tricyclic antidepressants. J Clin Psychopharmacol 2005, 25:515-520.
• [33]Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P: Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004, 25:563-568.
• [34]Paus R, Theoharides TC, Arck PC: Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol 2006, 27:32-39.
• [35]Theoharides TC, Konstantinidou A: Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci 2007, 12:1615-1628.
• [36]Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC: Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res 1999, 849:1-15.
• [37]Dimitriadou V, Rouleau A, Trung Tuong MD, Newlands GJF, Miller HRP, Luffau G, Schwartz J-C, Garbarg M: Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience 1997, 77:829-839.
• [38]Theoharides TC, Spanos CP, Pang X, Alferes L, Ligris K, Letourneau R, Rozniecki JJ, Webster E, Chrousos G: Stress-induced intracranial mast cell degranulation. A corticotropin releasing hormone-mediated effect. Endocrinology 1995, 136:5745-5750.
• [39]Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC: Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci U S A 2006, 103:7759-7764.
• [40]Nicot A, Rowe WB, De Kloet ER, Betancur C, Jessop DS, Lightman SL, Quirion R, Rostene W, Berod A: Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus. J Neuroendocrinol 1997, 9:263-269.
• [41]Middleton EJ, Kandaswami C, Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000, 52:673-751.
• [42]Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, Theoharides TC: Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005, 145:934-944.
• [43]Miranda CL, Maier CS, Stevens JF: Flavonoids. Chichester: eLS. John Wiley & Sons, Ltd; 2012. doi:10. 1002/9780470015902. a0003068. pub2.
• [44]Uceyler N, Hauser W, Sommer C: Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011, 12:245.
• [45]Abbott NJ: Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000, 20:131-147.
• [46]Cocchiara R, Bongiovanni A, Albeggiani G, Azzolina A, Geraci D: Evidence that brain mast cells can modulate neuroinflammatory responses by tumor necrosis factor-? production. Neuroreport 1998, 9:95-98.
• [47]Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G: TNF-? transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 1997, 72:137-141.
• [48]Bachelet I, Levi-Schaffer F: Mast cells as effector cells: a co-stimulating question. Trends Immunol 2007, 28:360-365.
• [49]Salamon P, Shoham NG, Gavrieli R, Wolach B, Mekori YA: Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 2005, 60:1316-1319.
• [50]Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, Galli SJ: Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006, 176:2238-2248.
• [51]Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolferg A, Theoharides TC: Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008, 155:1076-1084.
• [52]Sachdeva AK, Kuhad A, Tiwari V, Arora V, Chopra K: Protective effect of epigallocatechin gallate in murine water-immersion stress model of chronic fatigue syndrome. Basic Clin Pharmacol Toxicol 2010, 2010:2010.
• [53]Sachdeva AK, Kuhad A, Tiwari V, Chopra K: Epigallocatechin gallate ameliorates chronic fatigue syndrome in mice: behavioral and biochemical evidence. Behav Brain Res 2009, 205:414-420.
• [54]Vij G, Gupta A, Chopra K: Modulation of antigen-induced chronic fatigue in mouse model of water immersion stress by naringin, a polyphenolic antioxidant. Fundam Clin Pharmacol 2009, 23:331-337.
• [55]Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K: Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. Immunobiology 2009, 214:33-39.
• [56]Sachdeva AK, Kuhad A, Chopra K: Epigallocatechin gallate ameliorates behavioral and biochemical deficits in rat model of load-induced chronic fatigue syndrome. Brain Res Bull 2011, 86:165-172.
• [57]Ottenweller JE, Natelson BH, Gause WC, Carroll KK, Beldowicz D, Zhou XD, LaManca JJ: Mouse running activity is lowered by Brucella abortus treatment: a potential model to study chronic fatigue. Physiol Behav 1998, 63:795-801.
• [58]Surapaneni DK, Adapa SR, Preeti K, Teja GR, Veeraragavan M, Krishnamurthy S: Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats. J Ethnopharmacol 2012, 143:91-99.
• [59]Moser B, Wolf M, Walz A, Loetscher P: Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004, 25:75-84.
• [60]Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
• [61]Koelink PJ, Overbeek SA, Braber S, De KP, Folkerts G, Smit MJ, Kraneveld AD: Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther 2012, 133:1-18.
• [62]Juremalm M, Nilsson G: Chemokine receptor expression by mast cells. Chem Immunol Allergy 2005, 87:130-144.
• [63]Oliveira SH, Lukacs NW: Stem cell factor and IgE-stimulated murine mast cells produce chemokines (CCL2, CCL17, CCL22) and express chemokine receptors. Inflamm Res 2001, 50:168-174.
• [64]Sandig H, Bulfone-Paus S: TLR signaling in mast cells: common and unique features. Front Immunol 2012, 3:185.
• [65]Matsushima H, Yamada N, Matsue H, Shimada S: TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004, 173:531-541.
• [66]Orinska Z, Bulanova E, Budagian V, Metz M, Maurer M, Bulfone-Paus S: TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood 2005, 106:978-987.
• [67]Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ: Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003, 4:974-981.
• [68]Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
• [69]Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
• [70]Okayama Y: Mast cell-derived cytokine expression induced via Fc receptors and Toll-like receptors. Chem Immunol Allergy 2005, 87:101-110.
• [71]Vercammen E, Staal J, Beyaert R: Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin Microbiol Rev 2008, 21:13-25.
• [72]Saluja R, Delin I, Nilsson GP, Adner M: FcepsilonR1-mediated mast cell reactivity is amplified through prolonged Toll-like receptor-ligand treatment. PLoS One 2012, 7:e43547.
• [73]Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD: Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol 2004, 114:174-182.
• [74]Lappalainen J, Rintahaka J, Kovanen PT, Matikainen S, Eklund KK: Intracellular RNA recognition pathway activates strong anti-viral response in human mast cells. Clin Exp Immunol 2013, 172:121-128.
• [75]Huang Z, Mochizuki T, Watanabe H, Kagoshima M, Maeyama K: Biphasic evaluation of plasma histamine induced by water immersion stress, and their sources in rats. Eur J Pharmacol 1998, 360:139-146.
• [76]Huang M, Berry J, Kandere K, Lytinas M, Karalis K, Theoharides TC: Mast cell deficient W/Wv mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. Intl J Immunopathol Pharmacol 2002, 15:249-254.
• [77]Ding W, Liu Y: Genistein attenuates genioglossus muscle fatigue under chronic intermittent hypoxia by down-regulation of oxidative stress level and up-regulation of antioxidant enzyme activity through ERK1/2 signaling pathway. Oral Dis 2011, 17:677-684.
• [78]Jia Z, Zhen W, Velayutham Anandh BP, Liu D: Phytoestrogen genistein protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of RhoA signaling. Endocrinology 2013, 154:727-737.
• [79]Ji G, Zhang Y, Yang Q, Cheng S, Hao J, Zhao X, Jiang Z: Genistein suppresses LPS-induced inflammatory response through inhibiting NF-kappaB following AMP kinase activation in RAW 264.7 macrophages. PLoS One 2012, 7:e53101.
• [80]Yamashita S, Tsukamoto S, Kumazoe M, Kim YH, Yamada K, Tachibana H: Isoflavones suppress the expression of the FcepsilonRI high-affinity immunoglobulin E receptor independent of the estrogen receptor. J Agric Food Chem 2012, 60:8379-8385.
• [81]Kuo YH, Tsai WJ, Loke SH, Wu TS, Chiou WF: Astragalus membranaceus flavonoids (AMF) ameliorate chronic fatigue syndrome induced by food intake restriction plus forced swimming. J Ethnopharmacol 2009, 122:28-34.
• [82]Gupta A, Vij G, Chopra K: Possible role of oxidative stress and immunological activation in mouse model of chronic fatigue syndrome and its attenuation by olive extract. J Neuroimmunol 2010, 226(1¿2):3-7.
• [83]Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136.
• [84]Hess J, Angel P, Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004, 117:5965-5973.
• [85]Fraga CG, Oteiza PI: Dietary flavonoids: role of (-)-epicatechin and related procyanidins in cell signaling. Free Radic Biol Med 2011, 51:813-823.
• [86]Surh YJ, Kundu JK, Na HK: Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008, 74:1526-1539.
• [87]Yang Y, Oh JM, Heo P, Shin JY, Kong B, Shin J, Lee JC, Oh JS, Park KW, Lee CH, Shin YK, Kweon DH: Polyphenols differentially inhibit degranulation of distinct subsets of vesicles in mast cells by specific interaction with granule-type-dependent SNARE complexes. Biochem J 2013, 450:537-546.
• [88]Macready AL, Kennedy OB, Ellis JA, Williams CM, Spencer JP, Butler LT: Flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies. Genes Nutr 2009, 4:227-242.
• [89]Casini ML, Marelli G, Papaleo E, Ferrari A, D'Ambrosio F, Unfer V: Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. Fertil Steril 2006, 85:972-978.
• [90]Duffy R, Wiseman H, File SE: Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. Pharmacol Biochem Behav 2003, 75:721-729.
• [91]Davis JM, Murphy EA, Carmichael MD, Davis B: Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1071-R1077.
• [92]Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ: Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 2004, 36:592-604.
• [93]Ishisaka A, Ichikawa S, Sakakibara H, Piskula MK, Nakamura T, Kato Y, Ito M, Miyamoto K, Tsuji A, Kawai Y, Terao J: Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. Free Radic Biol Med 2011, 51:1329-1336.
• [94]Inoue T, Suzuki Y, Ra C: Epigallocatechin-3-gallate inhibits mast cell degranulation, leukotriene C4 secretion, and calcium influx via mitochondrial calcium dysfunction. Free Radic Biol Med 2010, 49:632-640.
• [95]Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ, Singh TS, Ha JH, Lee MG, Kim JE, Hyun MC, Kwon TK, Kim YH, Kim SH: Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch Pharm Res 2008, 31:1303-1311.
• [96]Shin HY, Kim SH, Jeong HJ, Kim SY, Shin TY, Um JY, Hong SH, Kim HM: Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. Int Arch Allergy Immunol 2007, 142:335-344.
• [97]Kumar A, Goyal R: Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. J Med Food 2008, 11:469-473.
• [98]Asadi S, Zhang B, Weng Z, Angelidou A, Kempuraj D, Alysandratos KD, Theoharides TC: Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells. Int J Immunopathol Pharmacol 2010, 23:1015-1020.
• [99]Jang S, Kelley KW, Johnson RW: Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A 2008, 105:7534-7539.
• [100]Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, Sen E: Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007, 73:55-63.
• [101]Jager AK, Saaby L: Flavonoids and the CNS. Molecules 2011, 16:1471-1485.
• [102]Jones QR, Warford J, Rupasinghe HP, Robertson GS: Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci 2012, 33:602-610.
• [103]Theoharides TC, Zhang B, Conti P: Decreased mitochondrial function and increased brain inflammation in bipolar disorder and other neuropsychiatric diseases. J Clin Psychopharmacol 2011, 31:685-687.
• [104]Aguirre A, Maturana CJ, Harcha PA, Saez JC: Possible involvement of TLRs and hemichannels in stress-induced CNS dysfunction via mastocytes, and glia activation. Mediators Inflamm 2013, 2013:893521.
• [105]Skaper SD, Giusti P, Facci L: Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 2012, 26:3103-3117.
• [106]Galli SJ, Borregaard N, Wynn TA: Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011, 12:1035-1044.
• [107]St John AL, Abraham SN: Innate immunity and its regulation by mast cells. J Immunol 2013, 190:4458-4463.
• [108]Theoharides TC: Mast cell: a neuroimmunoendocrine master player. Int J Tissue React 1996, 18:1-21.
• [109]Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, Donald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, et al.: Genomic responses in mouse models poorly mimic human inflammatory diseases. PNAS 2013, 110:3507-3512.